SyntheticMR, a front-runner in the field of quantitative imaging software, recently revealed that its SyMRI 15 solution has been granted 510(k) approval by the US Food and Drug Administration (FDA), allowing it to replace traditional diagnostic images.
The SyMRI 15 system revolutionizes MRI processes through its advanced synthetic imaging capabilities, offering a modern alternative to conventional imaging practices. Widely proven through rigorous multi-center studies at prestigious institutions across the United States, this solution has demonstrated its potential to streamline imaging workflows, serving as an alternative to traditional 3D imaging methods while uniquely providing tissue quantification. The technology significantly boosts efficiency and productivity, ensuring it meets the highest standards for diagnostic precision.
With SyMRI, a comprehensive array of contrast-enhanced images and quantitative patient data can be achieved through a single, swift scan, empowering users to enhance their imaging procedures and provide objective decision support in their clinical practice.
SyntheticMR AB specializes in creating and distributing forward-thinking software solutions for Magnetic Resonance Imaging (MRI). Their SyMRI technology offers a variety of customizable contrast images and detailed measurement data, all extracted from a quick, 5-minute scan.